Alivus Life Sciences LimitedALIVUSCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Dec 2025 1 quarters of data

₹1,309.50

MCap ₹16,077 Cr

Alivus Life Sciences Limited — Stock analysis & AI research Alivus Life Sciences Limited — Multibagger AI analysis Alivus Life Sciences Limited — Seasonality — best & worst months Alivus Life Sciences Limited — Technical indicators & charts Alivus Life Sciences Limited — Technical setup — score, trend, support & resistance Alivus Life Sciences Limited — Bull Flag pattern forming Alivus Life Sciences Limited — Live exchange announcements

📋 High ROCE Stocks 📋 High Operating Margin Stocks 📋 High Interest Coverage Stocks 📋 Low Debt Stocks 📋 High Promoter Holding Stocks 📋 Small Cap Stocks List 📈 Bollinger Squeeze Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹673 Cr

Sales · Dec 2025

₹231 Cr

Operating Profit · Dec 2025

34.4%

OPM % · Dec 2025

₹150 Cr

Net Profit · Dec 2025

₹12.25

EPS · Dec 2025

📝 Alivus Life Sciences Limited — results explained

Quarter ended December 2025 (Q3 FY26)

Alivus Life Sciences Limited reported revenue of ₹673 crore for the quarter ended December 2025 (Q3 FY26).

Net profit stood at ₹150 crore. Earnings per share (EPS) came in at ₹12.25.

Operating profit stood at ₹231 crore — an operating margin (OPM) of 34.4%.

Valuation snapshot

At the current price of ₹1,309.50, ALIVUS has a market capitalisation of ₹16,077 crore.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 25th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 74.85%, foreign institutional investors (FIIs) 5.93%, domestic institutional investors (DIIs) 7.03%, public shareholders 12.19% of Alivus Life Sciences Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹16,077 Cr

Current Price ?

₹1,309.5

P/E ?

N/A

Industry P/E ?

35.00

P/B ?

4.82

P/S ?

N/A

P/FCF ?

62.07

Enterprise Value ?

₹16,134 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

0.38%

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

25.0%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹673 Cr

PAT — latest qtr ?

₹150 Cr

YoY qtr sales growth ?

N/A

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹57 Cr

Debt to Equity ?

0.02

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

74.85%

Change in promoter holding ?

-0.09%

Pledged percentage ?

N/A

Market

Return 3 months ?

15.5%

Return 6 months ?

22.4%

🗓️ Quarterly results (1 quarters · ₹ Cr)

same fiscal quarter as Dec bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Dec 2025	YoY %	QoQ %
Sales	673	—	—
Operating Profit	231	—	—
Other Income	14	—	—
Interest	1	—	—
Depreciation	20	—	—
Profit Before Tax	198	—	—
Net Profit	150	—	—
EPS	12.25	—	—
OPM %	34.4%	—	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	25	25	25	25	+0.0%
Reserves	2,114	2,308	2,793	3,308	+18.4%
Borrowings	19	17	57	57	+0.0%
Other Liabilities	545	501	537	594	+10.6%
Total Liabilities	2,702	2,850	3,411	3,983	+16.8%
Fixed Assets	781	805	955	1,048	+9.7%
CWIP	62	106	102	273	+167.6%
Investments	0	0	478	780	+63.2%
Other Assets	1,860	1,939	1,877	1,881	+0.2%
Total Assets	2,702	2,850	3,411	3,983	+16.8%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
CFO/OP	71%	85%	81%	93%	+14.8%
Cash from Operating Activity	306	414	392	565	+44.1%
Cash from Investing Activity	-147	-116	-616	-570	+7.5%
Cash from Financing Activity	-388	-279	-6	-64	-966.7%
Net Cash Flow	-228	18	-230	-69	+70.0%
Free Cash Flow	143	285	226	259	+14.6%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	136	122	148	153	+3.4%
Inventory Days	224	251	237	237	+0.0%
Days Payable	158	139	137	127	-7.3%
Cash Conversion Cycle	202	235	248	263	+6.0%
Working Capital Days	176	188	201	306	+52.2%
ROCE %	30%	28%	25%	25%	+0.0%

👥 Shareholding (latest 5 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Sep 2026	% Chg
Promoters	74.94%	74.91%	74.91%	74.87%	74.85%	-0.0%
FIIs	6.42%	6.84%	5.08%	5.30%	5.93%	+11.9%
DIIs	5.62%	5.47%	7.13%	7.27%	7.03%	-3.3%
Public	13.03%	12.79%	12.89%	12.55%	12.19%	-2.9%
No. of Shareholders	1,38,500	1,35,643	1,32,748	1,27,969	1,22,777	-4.1%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SUNPHARMA Sun Pharmaceutical	₹1,840.00	441,478	36.5	59,911	12,104	29.8%	20.2%	11.2%	5.1%	10.5%	27.0%
2	DIVISLAB Divi's Laboratories	₹9,235.00	245,160	83.8	11,230	2,925	35.3%	26.0%	12.8%	16.7%	27.8%	65.5%
3	TORNTPHARM Torrent Pharmaceuticals	₹4,931.00	187,559	87.1	15,723	2,156	33.0%	13.7%	21.4%	11.9%	54.8%	3.3%
4	ZYDUSLIFE Zydus Lifesciences	₹1,162.20	115,930	23.2	27,148	5,070	31.2%	18.7%	16.8%	12.0%	16.2%	14.5%
5	CIPLA Cipla	₹1,366.00	110,353	32.7	28,324	3,356	18.7%	11.8%	2.2%	-26.7%	2.3%	-39.2%
6	LAURUSLABS Laurus Labs	₹1,969.00	106,387	97.2	7,270	1,090	28.0%	15.0%	22.7%	147.9%	29.1%	123.9%
7	DRREDDY Dr. Reddy's	₹1,165.50	97,085	29.3	28,704	3,273	15.3%	11.4%	-10.4%	-25.8%	-5.6%	-69.2%
8	AUROPHARMA Aurobindo Pharma	₹1,679.80	96,652	26.2	34,935	3,711	20.3%	10.6%	6.1%	0.6%	16.3%	25.2%
9	LUPIN Lupin	₹2,095.00	95,797	17.9	27,958	5,356	31.5%	19.2%	23.1%	62.0%	31.9%	87.8%
10	MANKIND Mankind Pharma	₹2,280.00	94,174	46.1	14,738	2,067	26.0%	14.0%	16.3%	-3.7%	12.9%	29.1%
11	GLENMARK Glenmark Pharmaceuticals	₹2,419.20	68,276	38.0	17,737	1,797	27.0%	10.1%	-61.2%	-67.4%	23.1%	927.9%
12	ALKEM Alkem Laboratories	₹5,243.50	62,694	29.1	15,081	2,187	20.1%	14.5%	13.5%	7.6%	10.9%	-21.6%
13	ABBOTINDIA Abbott India	₹25,860.00	54,951	34.0	7,005	1,615	28.1%	23.1%	8.1%	9.7%	4.4%	17.2%
14	IPCALAB Ipca Laboratories	₹1,964.20	49,833	38.0	10,125	1,379	22.0%	13.6%	7.9%	55.0%	20.8%	82.2%
15	GLAND Gland Pharma	₹2,935.90	48,433	47.1	6,431	1,028	25.3%	16.0%	-64.7%	-48.4%	22.3%	96.7%
16	AJANTPHARM Ajanta Pharma	₹3,398.90	42,472	37.4	5,777	1,135	25.4%	19.7%	17.3%	14.8%	24.8%	30.9%
17	JBCHEPHARM J. B.	₹2,416.10	38,793	53.4	4,148	709	26.7%	17.1%	5.9%	7.5%	-4.8%	-30.7%
18	EMCURE EMCURE PHARMACEUTICALS	₹1,975.10	37,470	37.0	9,684	1,019	20.4%	10.5%	16.6%	33.1%	22.8%	36.0%
19	WOCKPHARMA Wockhardt	₹2,021.50	32,848	92.5	3,133	353	19.9%	11.3%	-2.3%	342.1%	25.9%	199.1%
20	NEULANDLAB Neuland Laboratories	₹23,455.00	30,093	82.7	2,023	365	28.4%	18.0%	37.0%	40.2%	136.3%	666.0%
21	PPLPHARMA Piramal Pharma	₹211.50	28,024	113.5	9,206	247	11.0%	2.7%	-3.1%	-37.9%	17.4%	-161.3%
22	GRANULES Granules India	₹885.60	21,945	32.8	5,633	663	22.7%	11.8%	19.7%	18.8%	22.0%	59.3%
23	CAPLIPOINT Caplin Point	₹2,752.60	20,923	31.4	2,287	678	34.8%	29.7%	12.9%	20.2%	19.6%	18.8%
24	ERIS Eris Lifesciences	₹1,358.00	18,820	29.0	3,230	666	35.2%	20.6%	8.2%	72.6%	13.0%	14.6%
25	ALIVUS Alivus Life	₹1,322.70	16,239	26.9	2,590	603	32.3%	23.3%	6.9%	16.5%	6.4%	31.2%

❓ Frequently asked questions

What was Alivus Life Sciences Limited's revenue in Q3 FY26?